GET DAILY SIGNALSTyra Biosciences (TYRA) Readies Q3 2026 Earnings: Pipeline Progress and Spending in Focus
Key Takeaways
- Tyra Biosciences is expected to report its third-quarter 2026 results after the market closes on November 4, 2026, with the conference call scheduled for 4:00 p.m. Eastern Time.
- Wall Street consensus calls for a net loss of approximately $0.67 per share, compared with a loss of $0.50 per share in the same quarter a year ago.
- As a clinical-stage biotech, the company is expected to report zero product revenue, so investors will focus on cash burn, operating expenses, and pipeline milestones rather than sales.
- Research and development (R&D) spending has climbed as Tyra advances its lead FGFR3 inhibitor, dabogratinib, across multiple Phase 2 trials.
- The company ended its most recent quarter with a cash runway extending into the second half of 2028, providing meaningful financial flexibility.
- Tyra has missed consensus EPS estimates in its last two reported quarters, raising the bar for this release.
Why Quarterly Results Matter for Pre-Revenue Biotechs
For a pre-revenue biotechnology company, quarterly earnings are less about top-line growth and more about execution, spending discipline, and clinical momentum. TYRA is developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology — proteins involved in cell growth that are implicated in certain cancers and genetically defined bone conditions. Because the company generates no product sales, investors read its results primarily as a signal of how efficiently management is deploying capital and how quickly its pipeline is advancing. With multiple Phase 2 readouts expected across 2026, this report offers a timely checkpoint on both the balance sheet and the broader development strategy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Expect This Quarter
Analysts expect TYRA to post a net loss of roughly $0.67 per share for the third quarter of 2026, within a consensus estimate range of approximately $0.76 to $0.60. That compares with a loss of $0.50 per share in the prior-year quarter. Revenue is expected to remain at zero, consistent with the company's clinical-stage status.
Recent quarters have trended below expectations. In the second quarter of 2026, TYRA reported a loss of $0.69 per share, missing the $0.65 consensus, and recorded a GAAP net loss of about $45.6 million. R&D expenses rose to roughly $39.2 million as the company accelerated enrollment across its dabogratinib studies. For the full fiscal year 2026, the Street models a loss of approximately $2.68 per share. Given that two straight quarters came in short of estimates, investors will be watching whether the company's spending trajectory and loss per share align with forecasts this time.
Market Reaction and Investor Sentiment
Sentiment heading into this release reflects a mixture of pipeline optimism and earnings-related caution. Wall Street analysts maintain a broadly bullish stance, with a consensus rating of Strong Buy and an average price target well above recent trading levels. However, the stock has struggled since its August 2026 report, when shares fell sharply after a wider-than-expected loss. The stock's post-earnings announcement drift since that release has been negative, suggesting investors are demanding clearer evidence that rising spending is translating into near-term clinical value. Key risk factors include the timing and durability of upcoming Phase 2 data, continued operating-loss growth, and any unexpected delays in trial enrollment.
Forward Outlook and Key Factors to Monitor
The most important catalysts for TYRA extend well beyond a single quarter's income statement. Management has described 2026 as a pivotal year, with several data readouts expected across its pipeline of FGFR-targeting medicines.
At the center of the story is dabogratinib, the company's lead FGFR3-selective inhibitor. Investors are watching its Phase 2 trials closely, including BEACH301 in pediatric achondroplasia (ACH), a genetic condition that affects bone growth, and SURF302 in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC). A related study, SURF303, is expected to begin dosing patients with low-grade upper tract urothelial carcinoma (LG-UTUC), a cancer of the upper urinary tract, during 2026.
Beyond dabogratinib, TYRA is advancing TYRA-430, an FGFR4/3-biased inhibitor in hepatocellular carcinoma (HCC), the most common form of liver cancer, and TYRA-200, an FGFR1/2/3 inhibitor in intrahepatic cholangiocarcinoma (ICC), a rare bile-duct cancer. Enrollment progress and any early safety or efficacy signals in these programs could shape sentiment.
From a financial standpoint, the key variable to monitor is the pace of R&D spending against the company's cash runway, which extends into the second half of 2028. As long as losses remain funded, attention will stay fixed on whether upcoming clinical readouts validate the pipeline and support the stock's premium valuation.
Exploring AI Tools for Biotech Analysis
In my view, tools like Tickeron’s AI Screener provide a useful way to scan for comparable setups and track technical signals alongside fundamental updates. I’ve found it helpful when reviewing names in the sector to quickly surface related ideas and compare performance metrics without manually digging through dozens of filings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TYRA's RSI Indicator recovers from oversold territory
The RSI Oscillator for TYRA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 25 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on TYRA as a result. In 84 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for TYRA just turned positive on October 20, 2026. Looking at past instances where TYRA's MACD turned positive, the stock continued to rise in 48 of 55 cases over the following month. The odds of a continued upward trend are 87%.
Following a +0.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where TYRA advanced for three days, in 244 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
TYRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 63 cases where TYRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TYRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for TYRA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.061) is normal, around the industry mean (2.788). P/E Ratio (-8.741) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. TYRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement